Skip to content Skip to footer
Subscribe Now
PharmaShots Interview Takeda’s Elke Walter & Derek Wallace Share Insights on TAK-003 for Dengue & Zika Viruses
VIEWPOINTS

PharmaShots Interview: Takeda’s Elke Walter & Derek Wallace Share Insights on TAK-003 for Dengue & Zika Viruses

In an interview with PharmaShots, Elke Walter, Senior Director, Global Zika Program Lead & Derek Wallace, Vice President, Global Dengue Program Lead at Takeda share their views on TAK-003 & highlighted 10 presentations from dengue and zika programs at ASTMH Shots: The company reported a cumulative safety assessment included long-term safety data from the five…
March 23, 2022

Read more

PharmaShots Interview Astellas’ John C. Hairston & Gabriel P. Haas Share Insights on Xtandi (enzalutamide) for the Treatment of Prostate Cancer
VIEWPOINTS

PharmaShots Interview: Astellas’ John C. Hairston & Gabriel P. Haas Share Insights on Xtandi (enzalutamide) for the Treatment of Prostate Cancer

In an interview with PharmaShots, John C. Hairston, Sr. Medical Director, Oncology US Medical Affairs & Gabriel P. Haas, Senior Medical Director, Oncology Development Medical Sciences at Astellas share their views on the data of Xtandi (enzalutamide) over Active Surveillance for Localized Prostate Cancer Shots: The P-II (ENACT) study evaluates enzalutamide as monothx. vs active…
March 22, 2022

Read more

PharmaShots Interview Tillotts Pharma’s Adrian Hill & Christian Weidenfeller Share Insights on Dificlir (fidaxomicin) for the Treatment of Clostridioides Difficile Infection
VIEWPOINTS

PharmaShots Interview: Tillotts Pharma’s Adrian Hill & Christian Weidenfeller Share Insights on Dificlir (fidaxomicin) for the Treatment of Clostridioides Difficile Infection

In an interview with PharmaShots, Adrian Hill, Head of Commercial Operations & Christian Weidenfeller, Global Head of Medical Affairs Anti-Infectives at Tillotts Pharma share their views on the ESCMID recommendation for Dificlir (fidaxomicin) to treat Clostridioides Difficile Infection Shots: ·        Clostridioides difficile infection (CDI) is the leading cause of hospital-acquired infection · …
March 21, 2022

Read more

PharmaShots Interview Dermavant’s Philip Brown Shares Insight on the P-III (PSOARING 3) Study of Tapinarof
VIEWPOINTS

PharmaShots Interview: Dermavant’s Philip Brown Shares Insight on the P-III (PSOARING 3) Study of Tapinarof

In an interview with PharmaShots, Philip Brown, Chief Medical Officer at Dermavant share his views on the data of Tapinarof in the P-III (PSOARING 3) study for the treatment of Plaque Psoriasis & highlights new patient satisfaction data Shots: The P-III (PSOARING 3) extension study evaluates tapinarof (1%, qd) in adult patients with PsO for ~40wks. & a 4wks. safety follow-up period The…
March 15, 2022

Read more

PharmaShots Interview Jazz Pharmaceuticals’ Bruce C. Cozadd Shares Insight on Vision 2025 During the Virtual Presentation at 40th Annual J.P. Morgan Healthcare Conference 2022
VIEWPOINTS

PharmaShots Interview: Jazz Pharmaceuticals’ Bruce C. Cozadd Shares Insight on Vision 2025 During the Virtual Presentation at 40th Annual J.P. Morgan Healthcare Conference 2022

In an interview with PharmaShots, Bruce C. Cozadd, Chairman and Chief Executive Officer at Jazz Pharmaceuticals shared his views on Vision 2025 to deliver sustainable growth and enhanced value Shots: The company reported Vision 2025 to deliver sustainable growth and enhanced value to drive the transformation to an innovative, high-growth, global biopharmaceutical leader The company is expected to…
March 14, 2022

Read more

PharmaShots Interview Guardant Health’s Kathryn Lang Shares Insight on SHIELD Blood Test for Colorectal Cancer
VIEWPOINTS

PharmaShots Interview: Guardant Health’s Kathryn Lang Shares Insight on SHIELD Blood Test for Colorectal Cancer

In an interview with PharmaShots, Kathryn Lang, Vice President, Outcomes & Evidence at Guardant Health shared her views on the enrolment of the final patient in the (ECLIPSE) trial for SHIELD blood test to treat Colorectal Cancer Shots: The company has reported the patient enrolment in the (ECLIPSE) trial to evaluate SHIELD blood test in 12750 patients aged 45-84yr. with colorectal…
March 9, 2022

Read more

Load more